Erasca, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Erasca, Inc. (ERAS) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $78.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-11
- Erasca, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $19.50M, a 74.94% decline year-over-year.
- Erasca, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $58.55M, a 30.11% increase year-over-year.
- Erasca, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $77.83M.
- Erasca, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-03-31 was $45.00M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month |
|---|---|---|
| 2026-06-30 | $19.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $78.05M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $58.55M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $77.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $122.83M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $45.00M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |